T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Zoom
ZM
|
$2.88B |
| 2 |
Eli Lilly
LLY
|
$2.63B |
| 3 |
AstraZeneca
AZN
|
$1.96B |
| 4 |
Fortinet
FTNT
|
$1.66B |
| 5 |
Coupang
CPNG
|
$1.63B |
Top Sells
| 1 |
NXP Semiconductors
NXPI
|
$2.58B |
| 2 |
Morgan Stanley
MS
|
$2.29B |
| 3 |
Airbnb
ABNB
|
$2.07B |
| 4 |
NVIDIA
NVDA
|
$1.8B |
| 5 |
Qualcomm
QCOM
|
$1.79B |
Sector Composition
| 1 | Technology | 23.37% |
| 2 | Healthcare | 16.2% |
| 3 | Consumer Discretionary | 15.56% |
| 4 | Financials | 12.84% |
| 5 | Communication Services | 12.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
276
DELISTED
Acceleron Pharma Inc.
XLRN
| $727M | 0.07% |
5,358,304
+48,538
| +0.9% | +$6.58M |
|
277
Analog Devices
ADI
$122B
| $720M | 0.07% |
4,642,427
+296,759
| +7% | +$46M |
|
278
Broadridge
BR
$29.4B
| $719M | 0.07% |
4,698,878
+206,414
| +5% | +$31.6M |
|
279
Verizon
VZ
$187B
| $718M | 0.07% |
12,351,899
-4,006,864
| -24% | -$233M |
|
280
Pinduoduo
PDD
$177B
| $717M | 0.07% |
5,352,943
+1,446,170
| +37% | +$194M |
|
281
Select Medical
SEM
$1.62B
| $714M | 0.07% |
38,857,190
-2,158,136
| -5% | -$39.7M |
|
282
Amgen
AMGN
$153B
| $711M | 0.07% |
2,856,339
-204,010
| -7% | -$50.8M |
|
283
DuPont de Nemours
DD
$32.6B
| $695M | 0.07% |
8,996,223
-17,658,375
| -66% | -$1.36B |
|
284
Descartes Systems
DSGX
$9.26B
| $689M | 0.07% |
11,317,023
-236,176
| -2% | -$14.4M |
|
285
Revvity
RVTY
$10.1B
| $682M | 0.07% |
5,312,457
+1,992,799
| +60% | +$256M |
|
286
Franco-Nevada
FNV
$37.3B
| $677M | 0.07% |
5,401,881
+926,261
| +21% | +$116M |
|
287
Intel
INTC
$107B
| $664M | 0.07% |
10,375,146
+2,692,523
| +35% | +$172M |
|
288
Toro Company
TTC
$7.99B
| $662M | 0.07% |
6,422,441
+1,884,325
| +42% | +$194M |
|
289
BWX Technologies
BWXT
$15B
| $662M | 0.07% |
10,040,345
-228,134
| -2% | -$15M |
|
290
Rayonier
RYN
$4.12B
| $656M | 0.07% |
21,391,635
-845,365
| -4% | -$25.9M |
|
291
Costco
COST
$427B
| $656M | 0.07% |
1,861,666
-347,916
| -16% | -$123M |
|
|
NVRO
292
DELISTED
NEVRO CORP.
NVRO
| $655M | 0.07% |
4,694,704
+666,384
| +17% | +$93M |
|
293
Ascendis Pharma
ASND
$12.5B
| $654M | 0.07% |
5,073,336
-1,545,706
| -23% | -$199M |
|
294
TC Energy
TRP
$53.9B
| $652M | 0.07% |
14,255,241
-1,566,111
| -10% | -$71.7M |
|
295
Kimberly-Clark
KMB
$43.1B
| $650M | 0.07% |
4,674,541
+283,040
| +6% | +$39.4M |
|
296
Webster Financial
WBS
$10.3B
| $628M | 0.06% |
11,400,820
-1,192,994
| -9% | -$65.7M |
|
297
RPM International
RPM
$16.2B
| $627M | 0.06% |
6,822,629
+70,676
| +1% | +$6.49M |
|
298
CME Group
CME
$94.4B
| $625M | 0.06% |
3,058,118
-1,681,202
| -35% | -$343M |
|
299
Idexx Laboratories
IDXX
$51.4B
| $624M | 0.06% |
1,274,533
-737,860
| -37% | -$361M |
|
300
Expedia Group
EXPE
$26.6B
| $619M | 0.06% |
3,597,728
+3,357,964
| +1,401% | +$578M |
|